-
Je něco špatně v tomto záznamu ?
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib
V. Sandova, GM. Pavlasova, V. Seda, KA. Cerna, S. Sharma, V. Palusova, Y. Brychtova, S. Pospisilova, SM. Fernandes, A. Panovska, M. Doubek, MS. Davids, JR. Brown, J. Mayer, M. Mraz
Jazyk angličtina Země Itálie
Typ dokumentu dopisy, práce podpořená grantem
Grantová podpora
802644
European Research Council - International
R01 CA213442
NCI NIH HHS - United States
NLK
Directory of Open Access Journals
od 1994
Free Medical Journals
od 1994
Freely Accessible Science Journals
od 1994
PubMed Central
od 2009
Europe PubMed Central
od 2009
Open Access Digital Library
od 1994-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1996
- MeSH
- antigeny CD20 metabolismus MeSH
- chinazolinony farmakologie terapeutické užití MeSH
- chronická lymfatická leukemie * farmakoterapie MeSH
- interleukin-4 MeSH
- lidé MeSH
- protinádorové látky * terapeutické užití MeSH
- puriny farmakologie terapeutické užití MeSH
- transkripční faktor STAT6 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Medical Oncology Dana Farber Cancer Institute Boston MA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019646
- 003
- CZ-PrNML
- 005
- 20220804135848.0
- 007
- ta
- 008
- 220720s2021 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3324/haematol.2021.278644 $2 doi
- 035 __
- $a (PubMed)34196167
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Sandova, Veronika $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 245 10
- $a IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib / $c V. Sandova, GM. Pavlasova, V. Seda, KA. Cerna, S. Sharma, V. Palusova, Y. Brychtova, S. Pospisilova, SM. Fernandes, A. Panovska, M. Doubek, MS. Davids, JR. Brown, J. Mayer, M. Mraz
- 650 _2
- $a antigeny CD20 $x metabolismus $7 D018951
- 650 12
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukin-4 $7 D015847
- 650 12
- $a chronická lymfatická leukemie $x farmakoterapie $7 D015451
- 650 _2
- $a puriny $x farmakologie $x terapeutické užití $7 D011687
- 650 _2
- $a chinazolinony $x farmakologie $x terapeutické užití $7 D052999
- 650 _2
- $a transkripční faktor STAT6 $7 D050800
- 655 _2
- $a dopisy $7 D016422
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pavlasova, Gabriela Mladonicka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Seda, Vaclav $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Cerna, Katerina Amruz $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Sharma, Sonali $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Palusova, Veronika $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Brychtova, Yvona $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Pospisilova, Sarka $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Fernandes, Stacey M $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- 700 1_
- $a Panovska, Anna $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Doubek, Michael $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Davids, Matthew S $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- 700 1_
- $a Brown, Jennifer R $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- 700 1_
- $a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Mraz, Marek $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. marek.mraz@email.cz
- 773 0_
- $w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 106, č. 11 (2021), s. 2995-2999
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34196167 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135841 $b ABA008
- 999 __
- $a ok $b bmc $g 1823024 $s 1170889
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 106 $c 11 $d 2995-2999 $e 20211101 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
- GRA __
- $a 802644 $p European Research Council $2 International
- GRA __
- $a R01 CA213442 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20220720